Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma

British Journal of Cancer

Volumn 83, Issue 12, 2000, Pages 1594-1598

  Domenge, C ^a   Hill, C ^a   Lefebvre, J L ^b   De Raucourt, D ^c   Rhein, B ^d   Wibault, P ^a   Marandas, P ^a   Coche Dequeant, B ^b   Stromboni Luboinski, M ^a   Sancho Garnier, H ^a   Luboinski, B ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c Centre Antoine Baclesse   (France)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Chemotherapy; Cisplatin; Fluorouracil; Oropharyngeal cancer; Randomized trial

Indexed keywords

CISPLATIN; COBALT 60; FLUOROURACIL;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COBALT THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FATIGUE; FEMALE; FLUOROURACIL; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; NEOADJUVANT THERAPY; OROPHARYNGEAL NEOPLASMS; PROPORTIONAL HAZARDS MODELS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 17744364263     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1512     Document Type: Article

References (7)

1. Advanced carcinoma of the oropharynx: The value of the induction chemotherapy before loco-regional treatment. A retrospective study of 138 cases
2. Adjuvant chemotherapy with cis diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck
3. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: Three meta-analyses of updated individual data
4. A note on quantifying follow-up in studies of failure time
5. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and Cisplatin
6. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions